PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Macrogen to Use Blockchain for Genomic Big Data

Despite the high utilization value of DNA data within healthcare, data sharing in human genomics is a multifaceted challenge. Ethical considerations for use combined with the uniqueness of the genome of an individual require special precautions to enable sharing while protecting data privacy.
South-Korean biotech enterprise Macrogen, the country’s leading gene sequencing service provider, is developing a genomic big data blockchain-based platform together with a local tech firm Bigster.
According to a press release, Macrogen said that it is working with South Korean big data firm Bigster to develop a blockchain network to enhance security of personal genome information management and handle large volumes of data reliably. The two companies plan to complete the platform by June 2019.
Macrogen said genomic data, which carries critical information about a person’s biological makeup, could enable doctors to customize their patients’ diagnoses and treatment plans. The pharmaceutical industry can also use it for the development of new drugs and therapeutic agents.
Despite the high utilization value of DNA data within healthcare, data sharing in human genomics is a multifaceted challenge. Ethical considerations for use combined with the uniqueness of the genome of an individual require special precautions to enable sharing while protecting data privacy.
The firms’ envisioned platform will operate on a “private blockchain” in which only selected parties, such as pharmaceutical firms, research institutes, hospitals and genetic analysis startups, can participate. Macrogen believes this model would be “easy to expand and manage.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026